(PRTA) Prothena Corporation plc BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(PRTA) Prothena Corporation plc Complete Analysis Pack
See the Bigger Picture
This Prothena Corporation plc BCG Matrix helps you see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs, supporting strategy, research, and capital allocation decisions. The page already shows a real preview of the actual report content, so you can review the format and sample analysis before buying. Purchase the full version to get the complete ready-to-use BCG Matrix.
Stars
Birtamimab, Phase III, AL amyloidosis
Birtamimab is Prothena’s most advanced asset, and Phase III gives it the clearest near-term upside in the pipeline. AL amyloidosis is a rare, severe disease; advanced cardiac AL can carry median survival of about 6 months. That makes a successful readout a major value driver.
Prasinezumab, Phase IIb, Parkinson’s disease
Prasinezumab is one of Prothena Corporation plc’s lead neurodegeneration assets, and Parkinson’s disease affects about 10 million people worldwide, making it a large market. Phase IIb keeps the program in the most value-sensitive stage, where clinical readout can sharply re-rate the asset. In BCG terms, it fits a Star: high-growth need, but still tied to execution risk.
Roche alpha-synuclein collaboration
Roche alpha-synuclein collaboration is one of Prothena Corporation plc’s clearest Stars: it targets Parkinson’s, a disease affecting about 10 million people worldwide, and keeps Prothena in a high-value neuroscience asset without funding full launch costs. The Roche partnership lowers capital risk while preserving upside from a large, still-early market opportunity.
Bristol-Myers Squibb antibody collaboration
Bristol Myers Squibb's backing gives Prothena's antibody platform external validation, which is exactly what a Star needs. It also fits a biologics market that is already over $400 billion and still expanding, so the partnership supports future growth. By sharing development work with a large pharma partner, Prothena can cut its internal cash burn and keep capital for core programs.
- External validation from Bristol Myers Squibb
- Supports growth in biologics
- Lowers Prothena's capital burden
Neurodegeneration pipeline leadership
Prothena’s neurodegeneration pipeline sits in a strong Stars position because it targets Alzheimer’s, Parkinson’s, and amyloid-related disorders, all large unmet-need markets. In FY2025, the company reported $0 product revenue and $0.4 million collaboration revenue, so value still depends on pipeline execution, not sales.
- Focus: Alzheimer’s, Parkinson’s, amyloid
- High unmet need, high growth
- Pipeline drives the case
Prothena’s Late-Stage Pipeline Could Unlock Major Value
Prothena Corporation plc’s Stars are its late-stage neurodegeneration and amyloidosis assets: birtamimab, prasinezumab, and the Roche alpha-synuclein deal. Parkinson’s disease affects about 10 million people worldwide, and advanced cardiac AL amyloidosis can have median survival near 6 months, so the upside is tied to high unmet need. FY2025 revenue was $0 product revenue and $0.4 million collaboration revenue, so these programs still drive value.
| Star asset | Key data |
|---|---|
| Birtamimab | Phase III; AL amyloidosis |
| Prasinezumab | Phase IIb; Parkinson's |
| Roche deal | De-risks funding; preserves upside |
| FY2025 revenue | $0 product; $0.4M collaboration |
What is included in the product
Detailed Word Document
Prothena’s BCG Matrix maps its pipeline assets to guide invest, hold, or divest decisions.
Editable Excel File
Quick BCG snapshot for Prothena Corporation plc, highlighting each portfolio’s quadrant to simplify strategic decisions.
Reference Sources
Provides a concise source trail for Prothena Corporation plc, strengthening credibility and helping decision-makers verify key claims fast.
Cash Cows
No approved products
As of year-end 2025, Prothena Corporation plc had no approved or marketed medicine, so it had no mature product generating steady operating cash. That means there is no classic BCG "cash cow" in the portfolio. The company still depended on research spending and external funding, not product sales, to support operations.
No commercial sales base
Prothena Corporation plc stayed clinical-stage in FY2025, so it had no commercial product sales base and recorded zero product revenue. Its cash generation still depended on collaboration and milestone income, not recurring internal brand sales. That makes cash flow less stable than a true cash cow, because there is no approved product to scale.
Roche collaboration economics
Roche collaboration economics are Prothena Corporation plc’s closest cash-cow trait: non-dilutive funding from partnership payments, not share issuance. In FY2025, this kind of deal structure can add development-linked cash while preserving balance-sheet strength and limiting dilution.
Bristol-Myers Squibb collaboration economics
Bristol-Myers Squibb gives Prothena Corporation plc non-dilutive cash through upfront and milestone payments, so it can fund more science without paying for every program alone. That matters for a biotech with no commercial product, because collaboration cash can protect liquidity while R&D spend stays high.
In this model, the partnership acts like a cash cow inside the BCG view: lower internal burn, more external funding, and less pressure to raise capital at weak prices. The Bristol-Myers Squibb deal also keeps Prothena tied to a larger partner with deeper development spend.
- Non-dilutive funding supports liquidity.
- Shared costs reduce program burn.
- Milestones can extend cash runway.
Balance-sheet funding
For Prothena Corporation plc, Cash and investment resources are the real cash cow: they fund R&D, trials, and overhead before any product sales exist. In a clinical-stage model, this is balance-sheet funding, not product-driven cash generation, so liquidity is the buffer that keeps the pipeline alive.
At the latest reporting point, Prothena Corporation plc held a large cash and investment position versus no commercial product revenue, which is why this segment fits BCG support logic. One line: cash buys time.
- Funds trials and runway
- Covers losses without debt stress
- Supports pipeline optionality
Cash Kept Prothena’s Pipeline Alive in FY2025
Prothena Corporation plc had no true Cash Cow in FY2025 because it still had no approved product and no commercial revenue. The closest support came from collaboration cash and a strong cash-and-investments base, which funded R&D and extended runway. One line: cash, not product sales, kept the pipeline alive.
| Metric | FY2025 |
|---|---|
| Product revenue | 0 |
| Commercial products | 0 |
| Cash support | Non-dilutive |
What You See Is What You Get
Prothena Corporation plc Reference Sources
The Prothena Corporation plc BCG Matrix preview you see here is the exact document you’ll receive after purchase. No demo content, no placeholders—just the full, ready-to-use report. Once purchased, it’s available for immediate download and practical use.
Dogs
No marketed brands
Prothena Corporation plc has 0 marketed brands, so there is no approved commercial product to milk for steady margin. In FY2025, that also meant no mature sales base and no recurring product revenue stream to offset R&D burn. The Dogs bucket fits: the portfolio carries pipeline risk, not cash from a low-growth legacy brand.
No recurring product royalties
In fiscal 2025, Prothena Corporation plc still showed no recurring product royalty stream from marketed medicines, so there is no stable cash cow here. Cash inflow remains tied to development deals and milestones, not product sales, which keeps the profile growth-linked and volatile. That fits a Dogs view: weak cash durability, no mature royalty engine, and no low-growth cash trap to harvest.
Clinical-stage only
Prothena Corporation plc sits in Dogs because it still has no approved products, so value depends on clinical readouts and FDA wins. Its 2025 10-K shows the core issue: clinical-stage programs burn cash before revenue starts, which weakens BCG cash-return logic. That makes the stock a high-risk, capital-consuming asset, not a cash generator.
High burn, no sales
Prothena Corporation plc fits "High burn, no sales" because it still funds research and development without product revenue. In the latest reported year, it posted no product sales while R&D remained about $246 million, so cash keeps draining before any market fit is proven.
This is a classic biotech Dogs profile: high scientific spend, low near-term monetization, and ongoing dilution or financing risk. The business only improves if one pipeline asset turns into approved, revenue-making therapy.
- No product revenue
- R&D near $246 million
- Cash burn stays high
- Market fit not yet proven
No mature commercial infrastructure
Prothena Corporation plc has 0 approved commercial products, so it still lacks a mature sales force and broad distribution engine. That keeps near-term monetization weak and makes it hard to offset any underperforming asset with an existing brand base. In BCG terms, this is a classic Dogs setup: high R&D spend, but no commercial scale yet.
- No product sales engine
- 0 approved products
- Weak near-term monetization
- Little brand support
Prothena Burns Cash, With No Sales to Fund FY2025 R&D
Prothena Corporation plc fits Dogs: FY2025 had 0 approved products, no product revenue, and about $246 million in R&D spend. Cash came from deals and milestones, not sales, so the business still burned cash before any commercial base formed.
| FY2025 | Value |
|---|---|
| Approved products | 0 |
| Product revenue | $0 |
| R&D expense | ~$246M |
Question Marks
PRX012, Alzheimer’s disease
PRX012 is an early growth bet in Alzheimer’s, a CNS market with about 6.9 million U.S. patients age 65+ in 2024 and more than 55 million people worldwide. Prothena still needs human proof for PRX012, so sales are zero and market share is tiny. That makes it a classic question mark: big upside, high risk.
Dual Aß-Tau vaccine, treatment and prevention
Prothena Corporation plc’s dual Aβ-Tau vaccine sits in a huge market: Alzheimer’s disease affects about 55 million people worldwide, and U.S. dementia care costs topped $360 billion in 2024. But the program is still early and unproven, with no approved dual-epitope vaccine yet, so its low current share and high upside fit a classic question mark.
PRX005, Phase I, Alzheimer’s disease
PRX005 is a Phase I Question Mark: it sits in a huge Alzheimer’s market, but early human data are still the main gap. Alzheimer’s affects about 55 million people worldwide, yet PRX005 has no proven clinical share or sales base. Its upside is real, but until Phase I readouts show safety and target engagement, the asset stays highly uncertain.
PRX004, Phase I completed, transthyretin amyloidosis
PRX004 is still a Question Mark: it has only Phase I clinical data, so it lacks the late-stage proof needed for a commercial win. ATTR amyloidosis is a real niche, with tens of thousands of diagnosed patients in the U.S., but that market still needs stronger efficacy and safety validation.
- Phase I only, no Phase III.
- Niche ATTR market, still growing.
- Needs stronger data to rerate.
Prasinezumab, Phase IIb, Parkinson’s disease
Prasinezumab is a lead Phase IIb program for Parkinson’s disease, but it still has no approval and zero market share, so it fits the question mark box. Parkinson’s affects more than 10 million people worldwide, which gives the asset a large upside if it wins.
Prothena Corporation plc has not yet proven commercial demand or regulatory success for this asset, so its value is still highly uncertain. A positive late-stage readout could re-rate the program fast, but until then it remains speculative.
- Lead asset, but still unapproved
- Large Parkinson’s market opportunity
- No commercial traction yet
- Clear question mark in BCG terms
Prothena’s High-Upside, High-Risk Pipeline Targets Huge CNS Markets
Prothena Corporation plc’s question marks are mostly early-stage CNS and amyloid bets: PRX012, PRX005, PRX004, and prasinezumab. They target large markets, including about 55 million people with Alzheimer’s worldwide and more than 10 million with Parkinson’s, but all still lack approval and commercial sales. That means high upside, low share, and heavy trial risk.
| Asset | Stage | Market |
|---|---|---|
| PRX012 | Early | Alzheimer’s |
| Prasinezumab | Phase IIb | Parkinson’s |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.